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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
Aristada (aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult
patients?”
STUDY DESIGN: Review of three randomized controlled studies. All three trials were
conducted between 2014 and 2015.
DATA SOURCES: One randomized, controlled trial and two randomized, controlled, doubleblind trials found via Cochrane Library and PubMed.
OUTCOMES MEASURED: The outcomes that were measured include adverse events (pain at
injection site, insomnia, headache, toothache, abdominal discomfort, constipation, diarrhea,
akathisia, back pain, dyskinesia, dystonia, nasopharyngitis) measured by vital signs, physical
examination, and clinical laboratory tests. Improvement in psychotic symptoms measured by
PANSS (Positive and Negative Syndrome Scale) and CGI-I scale (Clinical Global ImpressionsImprovement Scale). Also, effect on agitation and hostility measured by PANSS, Personal and
Social Performance Scale, and disturbing and aggressive behavior.
RESULTS: The three randomized, controlled trials showed that the use of aripiprazole lauroxil
was effective at reducing symptoms of schizophrenia including hostility and agitation, based on
PANSS, CGI-I, and PSP scores. Results in reducing symptoms were seen as early as 8 days after
initial administration in some cases. Aripiprazole lauroxil was also found for be safe in the trials
with, only a limited number of mild to moderate adverse events occurring among certain
participants in the studies, mostly injection site pain.
CONCLUSIONS: Based on these three trials, Aristada (aripiprazole lauroxil) is a safe and
effective treatment option for schizophrenia in adult patients.
KEY WORDS: Aripiprazole lauroxil, schizophrenia
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Schizophrenia is a chronic and severe mental disorder that affects how a person thinks,
feels and behaves.4 Aripiprazole lauroxil is a new, novel LAI atypical antipsychotic that may be
used for the treatment of schizophrenia. This paper evaluates three randomized, controlled trials
comparing the effectiveness and safety of Aristada (aripiprazole lauroxil) in treating the
symptoms of schizophrenia in adult patients.
Schizophrenia is relevant to patients and Physician Assistant practice due to its
prevalence, cost to patients, and the number of health care visits per year from it. Schizophrenia
affects 7.2 individuals per 1,000 living in the United States and about 100,000 people living in
the country will be diagnosed this year.5 The overall United States health care cost of
schizophrenia was estimated to be $62.7 billion in 2002, with $5 billion of that for drugs alone.5
The 12 month health care use rate is 60% of adult patients with schizophrenia.4 Due to all of
these reasons, it is imperative for Physician Assistants to be aware of schizophrenia and the
burden that it places on patients who are affected by it.
The exact etiology of schizophrenia is unknown. It is a complex condition that is
increasingly being recognized as a collection of different disorders. Genetic influence has been
found to play a role. It is also being viewed from a developmental perspective.4 Symptoms of
schizophrenia are classified as “positive” or “negative”. The positive symptoms include
hallucinations, delusions, and thought disorders.4 The negative symptoms include lack of
motivation to accomplish goals, blunted affect or emotion, and lack of desire to form social
relationships.4 There is currently no curative treatment for schizophrenia, and its treatment is
aimed at symptom control.
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The typical first line treatment for schizophrenic patients is with atypical antipsychotics
or the older “typical” antipsychotics. Atypical antipsychotics include Risperidone, Quietiapine,
Olanzapine, Clozapine, Asenapine, and Ziprasidone. “Typical” antipsychotics include
Chlorpromazine, Fluphenazine, Haloperidol, and Perphenazine. Other treatment options include
psychosocial support, cognitive behavioral therapy, rehabilitation, and family support. Patients
may choose to utilize a combination of treatment options that work most effectively for control
of their symptoms. Due to lack of efficacy and contraindications to other treatment options,
Aristada (aripiprazole lauroxil) may be used as an effective treatment for schizophrenia in adult
patients.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is Aristada
(aripiprazole lauroxil) a safe and effective treatment for schizophrenia in adult patients?”
METHODS
The criteria used for selection of studies in this review included a population of adult
patients between the ages of 18 and 70 who have been diagnosed with schizophrenia and are
experiencing an acute exacerbation. The intervention was the administration of aripiprazole
lauroxil 441 mg IM or 882 mg IM. Comparisons were made between the treatment groups
receiving aripiprazole lauroxil to the experimental groups who received a placebo. Outcomes
measured included adverse events (pain at injection site, insomnia, headache, toothache,
abdominal discomfort, constipation, diarrhea, akathisia, back pain, dyskinesia, dystonia, and
nasopharyngitis), improvement in psychotic symptoms, and effect on agitation and hostility. The
studies included one randomized, controlled trial and two randomized, controlled, double-blind

	
  
	
  

	
  

	
  

	
  

	
  
Knowles, Schizophrenia, and Aristada 3

trials that evaluated aripiprazole lauroxil as an effective treatment for schizophrenia in adult
patients.
The key words used when searching for the articles included “schizophrenia” and
“aripiprazole lauroxil”. All of the chosen articles were published in English and in peerreviewed journals. The articles chosen were researched by the author and selected after being
searched via Cochrane Library and PubMed. The articles were selected based on relevance to
the clinical question, the types of studies, and whether or not the outcomes mattered to patients.
The inclusion criteria included patients aged 18 and up diagnosed with schizophrenia by DSMIV-TR criteria, and studies that were randomized, controlled trials evaluating efficacy and safety
of aripiprazole lauroxil. The exclusion criteria included studies with patients under the age of 18
years, and studies that did not provide information on efficacy of aripiprazole lauroxil in treating
schizophrenia. The statistics reported or used include p-values and percentages. Table 1
displays demographics and characteristics of included studies.
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Table 1: Demographics & Characteristics of included studies:
Study
Type
#
Age Inclusion
Exclusion Criteria W/D Interventions
Pts (yrs Criteria
)
1
Turncliff RCT
46
18- -Aged 18 to 55 -Suicidal
3
Aripiprazole
(2014)
55
yrs with
behavior/ideation
lauroxil 441
yrs chronic
-Any unstable
mg IM
schizophrenia medical illness
(Deltoid vs.
or
-Use of
Gluteal
schizoaffective aripiprazole within
administration)
disorder
60 days of
-BMI of 18 to screening
40 kg/m2
-Substance abuse
-On stable
within 3 months of
med >2
screening
months
-Women pregnant
-Previous
or breastfeeding
aripiprazole
-Corrected QT
use
interval
2
Meltzer
Double 623 18- -Aged 18-70
-Significant
262 Aripiprazole
(2015)
blind
70
with
medical illness
lauroxil 441
RCT
yrs schizophrenia -Women pregnant
mg & 882 mg
and
or breastfeeding
gluteal IM
experiencing
-Substance
an acute
dependence
exacerbation
-Previous
-PANSS score inadequate
of 70 to 120
response to
-Outpatient >3 aripiprazole
months
-Comorbid
cognitive disorder
3
Citrome
Double 622 18- -Aged 18-70
-Received long27
Aripiprazole
(2015)
blind
70
yrs with
acting
lauroxil 441
RCT
yrs schizophrenia antipsychotics and
mg & 882 mg
-Currently
agents that would
IM
experiencing
effect metabolism
acute
of aripiprazole
exacerbation
lauroxil
-Outpatient for - Currently
more than 3
hospitalized
months
involuntarily
-PANSS total -Use of MAO
score of 70 to inhibitors, lithium,
120
mood stabilizers
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OUTCOMES MEASURED
The outcomes measured in the trials were all patient-oriented evidence that matters. In
Turncliff et al study, the outcomes measured were safety evaluations for adverse events and
injection site reactions that were measured using clinical laboratory testing, physical
examination, vital signs, and 12-lead electrocardiogram.1 Blood samples were collected at prespecified times to determine plasma concentrations of the drug in the patients after IM dosing.1
The C-SSRS was used at screening, baseline, and during the trial to evaluate patients for suicidal
ideation, and the ESRS was used to evaluate patients for extrapyramidal symptoms.1 In Meltzer
et al study, the Positive and Negative Syndrome Scale (PANSS) and Clinical Global
Impressions-Severity of Illness scale(CGI-S) were used, along with the Clinical Global
Impressions-Improvement scale (CGI-I) to measure efficacy of aripiprazole lauroxil to improve
psychotic symptoms.2 Safety was also evaluated in Meltzer et al study, through monitoring
adverse events measured by vital signs, physical examination, ECG findings, injection site
reaction evaluation, and lab tests.2 In Citrome et al study, the effect of aripiprazole lauroxil on
agitation and hostility was measured using PANSS and the Personal and Social Performance
(PSP) scale.3 The PANSS Hostility item P7 and the PANSS-EC (excited component) were
components of PANSS used to determine the effects on agitation and hostility as well.
RESULTS
The three randomized, controlled trials in this EBM review all demonstrated statistical
results based on their respective studies.
In the Turncliff et al study, 38 (82.6%) of patients experienced at least one treatmentemergent adverse event. All of these adverse events were mild or moderate in intensity.1 The
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incidence of adverse events was higher in the deltoid administration group. The most common
adverse event was injection site pain in 20 (43.5%) subjects.1 The most common systemic
adverse events were headache (13.0%), insomnia (10.9%), and toothache (10.9%).1 The adverse
events of dyskinesia and dystonia each occurred in 3 subjects (13.6%) in the deltoid group, but
not the gluteal group. No severe adverse events occurred during the study and no
discontinuations due to adverse events occurred.1 No clinically significant effects of aripiprazole
lauroxil on vital signs, physical examination, or 12-lead electrocardiogram were found.1
Changes from clinical laboratory tests were small, with no patterns of change with time or
differences between the treatment groups observed.1 There were no clinically significant
changes from baseline for ESRS between treatment groups, and changes that occurred were
small.1 No post-baseline responses were noted on the C-SSRS, with no suicidal behavior or
attempts in any subjects.1
In the Meltzer et al study, a clinically meaningful change from baseline to day 85 in
PANSS total score was demonstrated for the aripiprazole lauroxil 441 mg and 882 mg groups,
with placebo-adjusted least squares mean differences of -10.9 (1.8) (P<.001) and -11.9 (1.8)
(P<.001).2 These improvements for both of the treatment groups were observed as early as day
8. Both the 441 mg and 882 mg groups had significantly better CGI-I scores at day 85 compared
to placebo (P<.001).2 A Wilcoxon rank sum test was used to determine this. The number of
patients who were much or very much improved was also significantly greater in both the 441
mg and 882 mg groups compared to placebo at every assessment after day 8. (P<.05 to P<.001).2
The study also looked at adverse events in a similar fashion to the Turncliff et al study. The
adverse events that occurred were mostly mild or moderate in intensity. The only serious
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adverse event that was considered related to the study drug was akathisia in a patient in the 882
mg group.2 More patients in the placebo group discontinued the study due to adverse events
(17.9%) compared to the 441 mg group (6.8%) or the 882 mg group (2.9%), attributed to
exacerbation of the underlying illness.2 Treatment-emergent adverse events occurred in ≥ 2% of
patients in the treatment groups. The most common of these were insomnia, akathisia, headache,
and anxiety.2 Akathisia was the only treatment-emergent adverse event that occurred with an
incidence ≥ 5% in each treatment group that was double the incidence in the placebo group.2
Most (>75%) of the episodes of akathisia occurred before the second injection of aripiprazole
lauroxil was administered. The incidence of injection site reactions was low overall, with 8
(3.9%), 12 (5.8%) and 4 (1.9%) patients for the 441 mg, 882 mg and placebo groups
respectively.2 The most common injection site reaction was pain, with redness, swelling or
induration rarely reported.2 Data on p-vales from the trial is included in Table 2.
Table 2

Placebo-adjusted least square

441 mg Aripiprazole Lauroxil

882 mg Aripiprazole Lauroxil

-10.9 (1.8)

-11.9 (1.8)

P<.001

P<.001

mean difference improvement
in PANSS baseline to day 85
P value

Placebo-adjusted mean change -14.7 (3.5)

-16.6 (3.4)

in PANSS day 85
P value

P<.0001

P<.0001
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Finally, in the Citrome et al study, the mean baseline PANSS total scores showed that
patients in the study were severely impaired (score >90).3 The mean total PSP score at baseline
was ≈	
 50, indicating severe difficulties with social and personal functioning.3 The proportion of
patients with a PANSS hostility item P7 more than 1 was significantly lower for each
aripiprazole lauroxil group compared to placebo at the end of the study.3 At day 85, aripiprazole
lauroxil 441 mg 53.6% (P=0.01), aripiprazole lauroxil 882 mg 46.1% (P<0.001) and placebo
66.3%.3 Statistically significant changes were also observed at days 22, 29, and 57 of the study.3
When measuring the PANSS excited component, a significant improvement (P<0.001) was
observed with both aripiprazole lauroxil groups compared with placebo at days 8, 15, 22, 29, 57,
and 85.3 The improvement was greater in the 882 mg group compared to the 441 mg group.
Significant improvements were observed for both aripiprazole lauroxil groups versus placebo for
the PSP disturbing and aggressive behavior domain at day 85. These results were placebo
44.1%, aripiprazole lauroxil 441 mg 30% (P=0.007 vs. placebo) and aripiprzole lauroxil 882 mg
22.2% (P<0.001 vs. placebo).
DISCUSSION
The three studies combined display evidence that Aristada can be used as both a safe and
effective treatment of schizophrenia. The Turncliff et al study demonstrated that IM
administration of aripiprazole lauroxil is tolerable in adult patients with chronic stable
schizophrenia.1 The higher incidence of injection site reactions in the deltoid administration
group shows that gluteal injections may be the preferred method in the future for patients who
have a lower tolerance for pain. The most common injection site reaction being pain is not
surprising as some small level of pain can be expected with IM injections. Still, only 43.5% of
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subjects experienced this adverse event.1 Patients who experience dyskinesia or dystonia may be
better served receiving their injection via gluteal administration as well since no subjects in the
gluteal group experienced those adverse events.1 The lack of clinically significant changes to
vital signs, physical examination, and ECG demonstrate that while some mild adverse events
may occur, overall it is safe to administer aripiprazole lauroxil IM. A limitation to this study was
the smaller amount of patients who participated in it.
The Meltzer et al study showed that clinically and statistically significant negative
changes occurred to the PANSS scores, meaning that both treatment groups were effective at
reducing the symptoms of schizophrenia.2 The drug may begin to work as early as 8 days after
administration as evidenced by the study.2 The statistically significant, improved CGI-I scores at
day 85 of the study also supports that Aristada can effectively treat schizophrenia.2 The greater
improvement in the PANSS total score in the 882 mg group suggests that it may be more
beneficial to administer a higher dose in patients with more severe symptoms.2 This randomized,
double-blind, placebo controlled trial also showed that Aristada is a safe option for schizophrenic
patients. Both doses were well tolerated among patients with the incidence of treatment
emergent adverse events remaining low and not appearing to be related to dose. Akathisia
occurred in patients in both groups and seemed to coincide with the first injection for the
majority of episodes. This is something that a follow-up study could more closely examine to
further investigate the incidence of adverse events of aripiprazole lauroxil.
The Citrome et al study showed similar results to the two previously mentioned trials.
The patients were found to have severe social and personal functioning based on PANSS scores
at baseline, and these improved dramatically after the administration of aripiprazole lauroxil.3
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The PANSS hostility item P7 improvements seen in patients, demonstrate that reductions in
hostile behaviors occurred.3 The reductions in aggressiveness and hostility are important to note
because these are symptoms commonly seen in schizophrenic patients. This study provides more
evidence that aripiprazole lauroxil can effectively reduce symptoms of schizophrenia in chronic
schizophrenics who are severely affected by the disorder.
CONCLUSION
Based on this systematic review and its included studies, Aristada (aripiprazole lauroxil)
is an effective and safe treatment for schizophrenia in adult patients. All three studies showed
that the drug was well tolerated and was able to reduce symptoms of schizophrenia. The risks of
the mild to moderate adverse events experienced by patients in the trials do not outweigh the
benefits of effectively reducing symptoms associated with schizophrenia including agitation and
hostility. Patients who wish to exhibit better control of their schizophrenic symptoms may find
Aristada to be their treatment method of choice. Aristada may still be combined with other
forms of treatment such as psychosocial support and cognitive behavioral therapy to achieve the
greatest individualized results for patients. Future studies on Aristada could focus on more longterm effectiveness of Aristada over the course of a year. Future studies could also focus on how
effective Aristada is when combined with other treatments for schizophrenia such as cognitive
behavioral therapy. There is still more research to be done about Aristada but the results of the
studies included in this evaluation demonstrate that it is a drug worth keeping on the radar of
Physician Assistants and other healthcare practitioners across the country. It is with the
knowledge of treatment options like Aristada that Schizophrenia can be effectively treated for
symptomatic control and to reduce healthcare costs.
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